Lyra Therapeutics (LYRA) Asset Utilization Ratio (2021 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Asset Utilization Ratio of 0.01 in Q4 2025, down 19.98% on a QoQ basis from 0.01 in Q3 2025, and down 52.83% YoY from 0.02 in Q4 2024.
Lyra Therapeutics (LYRA) Asset Utilization Ratio (2021 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Asset Utilization Ratio for 5 consecutive years, with 0.01 the latest figure, recorded in Q4 2025.
- Asset Utilization Ratio for Q4 2025 came in at 0.01, down 52.83% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.01 (down 52.83% YoY), and the FY2025 annual result was 0.01, down 47.09% from the prior year.
- Asset Utilization Ratio for Q4 2025 stood at 0.01, down from 0.01 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.02 in Q4 2024, with the low at 0.0 in Q4 2021.
- A 5-year average of 0.01 and a median of 0.01 in 2023 frame the typical range for Asset Utilization Ratio.
- Across the five-year window, Asset Utilization Ratio soared 155.62% in 2022 and slumped 52.83% in 2025, its largest moves.
- Lyra Therapeutics' Asset Utilization Ratio stood at 0.0 in 2021, then soared by 155.62% to 0.01 in 2022, then fell by 0.35% to 0.01 in 2023, then soared by 78.58% to 0.02 in 2024, then plunged by 52.83% to 0.01 in 2025.
- The last three Asset Utilization Ratio figures came in at 0.01 (Q4 2025), 0.01 (Q3 2025), and 0.01 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.01 |
| Sep 30, 2025 | 0.01 |
| Jun 30, 2025 | 0.01 |
| Mar 31, 2025 | 0.02 |
| Dec 31, 2024 | 0.02 |
| Sep 30, 2024 | 0.02 |
| Jun 30, 2024 | 0.02 |
| Mar 31, 2024 | 0.01 |
| Dec 31, 2023 | 0.01 |
| Sep 30, 2023 | 0.01 |
| Jun 30, 2023 | 0.01 |
| Mar 31, 2023 | 0.01 |
| Dec 31, 2022 | 0.01 |
| Sep 30, 2022 | 0.01 |
| Jun 30, 2022 | 0.01 |
| Mar 31, 2022 | 0.01 |
| Dec 31, 2021 | 0.00 |